Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $140

Barrington Research analyst Michael Petusky has maintained an 'Outperform' rating on Haemonetics (NYSE: HAE) and raised the price target from $118 to $140. This adjustment reflects a positive outlook on the company's performance.